PL216398B1 - Pochodna pirymidyny i jej zastosowanie oraz kompozycja ją zawierająca i pochodna benzenu - Google Patents

Pochodna pirymidyny i jej zastosowanie oraz kompozycja ją zawierająca i pochodna benzenu

Info

Publication number
PL216398B1
PL216398B1 PL368270A PL36827002A PL216398B1 PL 216398 B1 PL216398 B1 PL 216398B1 PL 368270 A PL368270 A PL 368270A PL 36827002 A PL36827002 A PL 36827002A PL 216398 B1 PL216398 B1 PL 216398B1
Authority
PL
Poland
Prior art keywords
formula
compound
mol
solvent
mixture
Prior art date
Application number
PL368270A
Other languages
English (en)
Polish (pl)
Other versions
PL368270A1 (en
Inventor
Jerome Emile Georges Guillemont
Patrice Palandjian
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Frederik Frans Desire Daeyaert
Jan Heeres
Aken Koen Jeanne Alfons Van
Paulus Joannes Lewi
Paul Adrian Jan Janssen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL216398(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A20-cv-00189 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL368270A1 publication Critical patent/PL368270A1/xx
Publication of PL216398B1 publication Critical patent/PL216398B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL368270A 2001-08-13 2002-08-09 Pochodna pirymidyny i jej zastosowanie oraz kompozycja ją zawierająca i pochodna benzenu PL216398B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01203090 2001-08-13
EP02077748 2002-06-10

Publications (2)

Publication Number Publication Date
PL368270A1 PL368270A1 (en) 2005-03-21
PL216398B1 true PL216398B1 (pl) 2014-03-31

Family

ID=26076978

Family Applications (2)

Application Number Title Priority Date Filing Date
PL368270A PL216398B1 (pl) 2001-08-13 2002-08-09 Pochodna pirymidyny i jej zastosowanie oraz kompozycja ją zawierająca i pochodna benzenu
PL402388A PL402388A1 (pl) 2001-08-13 2002-08-09 Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL402388A PL402388A1 (pl) 2001-08-13 2002-08-09 Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca

Country Status (37)

Country Link
US (8) US7125879B2 (instruction)
EP (3) EP2298761B1 (instruction)
JP (4) JP2005507380A (instruction)
KR (2) KR100969273B1 (instruction)
CN (2) CN100509801C (instruction)
AP (1) AP1610A (instruction)
AR (1) AR036387A1 (instruction)
AT (1) ATE517891T1 (instruction)
AU (1) AU2002329238C1 (instruction)
BE (3) BE2012C020I2 (instruction)
BR (3) BR122015023612B8 (instruction)
CA (1) CA2452217C (instruction)
CY (4) CY1112331T1 (instruction)
DE (1) DE122012000038I1 (instruction)
DK (2) DK3808743T3 (instruction)
EA (1) EA006656B1 (instruction)
EG (1) EG24684A (instruction)
ES (3) ES2923581T3 (instruction)
FR (3) FR12C0035I2 (instruction)
HR (3) HRP20040096B1 (instruction)
HU (5) HU230192B1 (instruction)
IL (2) IL160328A0 (instruction)
JO (1) JO3429B1 (instruction)
LT (3) LT3808743T (instruction)
LU (2) LU92001I2 (instruction)
MX (1) MXPA04001401A (instruction)
MY (1) MY189572A (instruction)
NO (3) NO327639B1 (instruction)
NZ (1) NZ530951A (instruction)
OA (1) OA12652A (instruction)
PA (1) PA8552901A1 (instruction)
PL (2) PL216398B1 (instruction)
PT (1) PT1419152E (instruction)
SI (2) SI1419152T1 (instruction)
UA (1) UA78221C2 (instruction)
WO (1) WO2003016306A1 (instruction)
ZA (1) ZA200401159B (instruction)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2475764C (en) 2002-03-13 2011-05-31 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
MXPA05001541A (es) * 2002-08-09 2005-04-19 Janssen Pharmaceutica Nv Procedimientos para la preparacion de 4-[[4 -[[4- (2-cianoetenil)- 2, 6-dimetilfenil] amino]-2 -pirimidinil] amino] benzonitrilo.
AU2003288198A1 (en) * 2002-11-28 2004-06-18 Schering Aktiengesellschaft CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents
HRP20050690A2 (en) * 2003-02-07 2006-08-31 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
PL227577B1 (pl) * 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
BRPI0412734A (pt) 2003-07-17 2006-09-26 Tibotec Pharm Ltd processo para preparação de partìculas que contêm um antiviral
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
CA2533320A1 (en) * 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) * 2003-09-03 2012-06-11 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
BRPI0414791A (pt) * 2003-09-25 2006-11-21 Janssen Pharmaceutica Nv derivados de purina inibidores da replicação do hiv
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
AU2005266312C1 (en) 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
BRPI0520870B8 (pt) 2004-08-25 2021-05-25 Ardea Biosciences Inc compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
SI1789139T1 (sl) * 2004-09-02 2012-08-31 Janssen Pharmaceutica Nv Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila
SI1632232T1 (sl) * 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
JP2008513515A (ja) 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
MX2007003796A (es) * 2004-09-30 2007-04-25 Tibotec Pharm Ltd Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
ATE520672T1 (de) * 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
DK1888537T3 (da) * 2005-05-26 2013-12-09 Janssen R & D Ireland Fremgangsmåde til fremstilling af 4[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitril
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EA014914B1 (ru) * 2006-01-20 2011-02-28 Тиботек Фармасьютикалз Лтд. Долговременное лечение вич-инфекции
DE602007009508D1 (de) 2006-03-30 2010-11-11 Little Island Co Cork Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
DK2004632T3 (da) 2006-03-30 2014-06-16 Janssen R & D Ireland Hiv-inhiberende 5-amidosubstituerede pyrimidiner
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
MX2009000158A (es) 2006-06-23 2009-01-23 Tibotec Pharm Ltd Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil ]-amino]-2-pirimidinil]-amino]-benzonitrilo.
CA2668997C (en) 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
RS53588B1 (en) 2006-12-08 2015-02-27 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
MX2009005881A (es) * 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
US8318736B2 (en) 2006-12-29 2012-11-27 Janssen R&D Ireland HIV inhibiting 5,6-substituted pyrimidines
EP2778155A1 (en) 2007-01-31 2014-09-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
UA97834C2 (ru) * 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
CA2687747C (en) 2007-05-30 2015-11-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
ES2437331T3 (es) * 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
CN101407476B (zh) * 2007-10-12 2012-07-18 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
KR101411806B1 (ko) 2007-11-27 2014-06-24 아디아 바이오사이언스즈 인크. 신규한 화합물 및 조성물과 사용 방법
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2731451A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CN102131809A (zh) 2008-07-23 2011-07-20 沃泰克斯药物股份有限公司 三环吡唑并吡啶激酶抑制剂
MX2011001319A (es) * 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
CN101717364B (zh) * 2008-10-09 2014-08-13 中国人民解放军军事医学科学院毒物药物研究所 作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
EP2351739B1 (en) 2008-10-09 2013-07-31 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
RU2546529C2 (ru) 2008-12-24 2015-04-10 Тиботек Фармасьютикалз Имплантируемые устройства для лечения вич
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
JP5627675B2 (ja) 2009-05-06 2014-11-19 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジン
ME03058B (me) 2010-01-27 2019-01-20 Viiv Healthcare Co Antivirusna terapija
MX2012008644A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasa de pirazolopiridinas.
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
WO2011094288A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
CA2815858C (en) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
HRP20140946T1 (hr) 2010-11-19 2015-02-13 Gilead Sciences, Inc. Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2702044B1 (en) 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
CN106518845B (zh) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
ES2680146T3 (es) * 2011-09-16 2018-09-04 Hetero Research Foundation Hidrocloruro de rilpivirina
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2825042B1 (en) 2012-03-15 2018-08-01 Celgene CAR LLC Salts of an epidermal growth factor receptor kinase inhibitor
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
US9139535B2 (en) * 2012-07-12 2015-09-22 Hetero Research Foundation Process for rilpivirine using novel intermediate
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
MX2017003928A (es) 2014-09-26 2017-06-28 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada.
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
SI3316868T1 (sl) 2015-06-30 2020-04-30 Gilead Sciences, Inc. Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) * 2016-07-04 2018-08-21 宜昌人福药业有限责任公司 一种有效去除利匹韦林异构体的方法
HRP20240118T1 (hr) 2016-10-24 2024-04-12 Janssen Sciences Ireland Unlimited Company Disperzivni pripravci
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) * 2016-12-08 2018-12-25 西北师范大学 一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) * 2017-02-27 2019-08-16 武汉工程大学 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
CN110958883A (zh) 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
CA3113234A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
CN109293581B (zh) * 2018-09-21 2020-03-27 宜昌人福药业有限责任公司 一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
MX2022000060A (es) * 2019-07-03 2022-04-18 Janssen Sciences Ireland Unlimited Co Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina.
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
EP4065121A4 (en) 2019-11-29 2023-11-29 Aptorum Therapeutics Limited RILPIVIRINE COMPOSITION AND USE THEREOF FOR THE TREATMENT OF TUMORS OR CANCER
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
AU2021302678A1 (en) * 2020-06-30 2023-02-09 University Of South Australia New therapeutic use of Rilpivirine
CN112028836B (zh) * 2020-09-09 2021-12-07 山东大学 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) * 2021-03-08 2021-07-13 复旦大学 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) * 2021-05-06 2021-10-01 复旦大学 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) * 2021-09-03 2021-12-28 复旦大学 一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
AU2022394742A1 (en) 2021-11-17 2024-07-04 Janssen Sciences Ireland Unlimited Company Dissolution test
TW202408516A (zh) 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 液體組成物
TW202406551A (zh) 2022-04-22 2024-02-16 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(一)
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
WO2023222755A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CN115490642B (zh) * 2022-09-21 2024-11-15 山东大学 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3953398A (en) * 1970-07-20 1976-04-27 The Goodyear Tire & Rubber Company Age resistant polymeric compositions
JPS5490121A (en) * 1977-11-28 1979-07-17 Boettcher Barry Neutral copper bonded body and antiinflaming agent
JPS63159316A (ja) * 1977-11-28 1988-07-02 アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド 中性銅結合体を含む抗炎症組成物
JPS5879920A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 血小板凝集阻害剤
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU725204B2 (en) 1995-11-23 2000-10-05 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP3990808B2 (ja) * 1998-03-26 2007-10-17 Ｔｄｋ株式会社 非水電解質電池用電極の製造方法
CZ299380B6 (cs) 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
JP2000035628A (ja) * 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
ATE342892T1 (de) * 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
EE05086B1 (et) * 1998-11-10 2008-10-15 Janssen Pharmaceutica N.V. Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
HK1045518A1 (zh) 1999-03-09 2002-11-29 法玛西雅厄普约翰美国公司 用作抗病毒剂的4-氧代-4，7-二氢-噻吩并[2，3-b]吡啶-5-甲酰胺类化合物
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2407754C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CN1494528A (zh) * 2001-03-02 2004-05-05 ʷ��˿�������ȳ�ķ���޹�˾ 作为逆转录酶抑制剂的二苯酮
DE60223790D1 (de) * 2001-03-29 2008-01-10 Vertex Pharma Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JP2005507874A (ja) * 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04010778A (es) * 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
MXPA05001541A (es) * 2002-08-09 2005-04-19 Janssen Pharmaceutica Nv Procedimientos para la preparacion de 4-[[4 -[[4- (2-cianoetenil)- 2, 6-dimetilfenil] amino]-2 -pirimidinil] amino] benzonitrilo.
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
US9226970B2 (en) * 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds

Also Published As

Publication number Publication date
CN101816658A (zh) 2010-09-01
US20190322628A1 (en) 2019-10-24
US20040198739A1 (en) 2004-10-07
EA200400304A1 (ru) 2004-08-26
NO2012010I2 (no) 2013-09-02
IL160328A0 (en) 2004-07-25
JO3429B1 (ar) 2019-10-20
ES2799408T3 (es) 2020-12-17
ZA200401159B (en) 2005-07-27
EP2298761B1 (en) 2020-03-25
NO337142B1 (no) 2016-02-01
BR122015032641B1 (pt) 2022-03-03
HUP0401346A2 (hu) 2004-12-28
JP4838396B2 (ja) 2011-12-14
CA2452217C (en) 2009-06-16
AP2004002993A0 (en) 2004-03-31
PT1419152E (pt) 2011-10-11
MXPA04001401A (es) 2004-05-27
CN100509801C (zh) 2009-07-08
US20180244632A1 (en) 2018-08-30
LTPA2012008I1 (lt) 2012-06-25
EP1419152B1 (en) 2011-07-27
CN1541215A (zh) 2004-10-27
EP3808743A1 (en) 2021-04-21
US20060252764A1 (en) 2006-11-09
CY2012013I2 (el) 2015-08-05
BE2022C531I2 (instruction) 2022-08-09
HUS1500051I1 (hu) 2018-05-28
BRPI0211909B8 (pt) 2021-05-25
JP5539927B2 (ja) 2014-07-02
PL368270A1 (en) 2005-03-21
JP2005507380A (ja) 2005-03-17
LTC3808743I2 (instruction) 2023-04-25
MY189572A (en) 2022-02-17
US10611732B2 (en) 2020-04-07
EA006656B1 (ru) 2006-02-24
KR20070101409A (ko) 2007-10-16
SI3808743T1 (sl) 2022-09-30
LTC1419152I2 (lt) 2025-05-12
HRP20120265B1 (hr) 2019-11-29
AR036387A1 (es) 2004-09-08
US7125879B2 (en) 2006-10-24
JP2011225589A (ja) 2011-11-10
US10370340B2 (en) 2019-08-06
JP2010077140A (ja) 2010-04-08
CN101816658B (zh) 2014-08-27
LT3808743T (lt) 2022-08-10
CA2452217A1 (en) 2003-02-27
NO327639B1 (no) 2009-09-07
BE2012C020I2 (instruction) 2021-07-19
PA8552901A1 (es) 2003-02-28
EP3808743B1 (en) 2022-07-20
HUS1500055I1 (hu) 2016-03-29
HUS2200038I1 (hu) 2022-08-28
HU231274B1 (hu) 2022-07-28
JP2011236221A (ja) 2011-11-24
BE2012C022I2 (instruction) 2022-01-12
US20120076835A1 (en) 2012-03-29
HRP20192051B1 (hr) 2022-05-27
BR0211909A (pt) 2004-08-24
EP2298761A1 (en) 2011-03-23
OA12652A (en) 2006-06-15
US20170121292A1 (en) 2017-05-04
KR100969273B1 (ko) 2010-08-20
FR12C0035I2 (fr) 2016-02-12
HK1145449A1 (en) 2011-04-21
HU230192B1 (hu) 2015-09-28
BR122015023612B1 (pt) 2021-01-19
FR12C0036I1 (instruction) 2012-06-29
PL402388A1 (pl) 2013-04-02
DK1419152T3 (da) 2011-10-24
HRP20120265A2 (hr) 2012-05-31
KR100817453B1 (ko) 2008-03-27
BR122015023612B8 (pt) 2021-05-25
FR12C0036I2 (fr) 2016-05-06
HRP20040096B1 (hr) 2013-06-30
CY2012012I2 (el) 2015-08-05
KR20040023645A (ko) 2004-03-18
WO2003016306A1 (en) 2003-02-27
US20170320835A1 (en) 2017-11-09
DK3808743T3 (da) 2022-08-01
HRP20192051A2 (hr) 2020-03-06
CY2022024I1 (el) 2023-01-05
LU92001I2 (fr) 2012-07-16
NZ530951A (en) 2005-10-28
US8080551B2 (en) 2011-12-20
CY2022024I2 (el) 2023-01-05
AU2002329238B2 (en) 2008-01-24
BRPI0211909B1 (pt) 2018-05-29
ATE517891T1 (de) 2011-08-15
EG24684A (en) 2010-05-05
IL160328A (en) 2011-01-31
US9981919B2 (en) 2018-05-29
CY1112331T1 (el) 2015-08-05
ES2923581T3 (es) 2022-09-28
HK1070066A1 (en) 2005-06-10
US9580392B2 (en) 2017-02-28
NO20083770L (no) 2004-03-12
NO2012010I1 (no) 2012-06-18
SI1419152T1 (sl) 2011-11-30
CY2012013I1 (el) 2015-08-05
EP1419152A1 (en) 2004-05-19
UA78221C2 (uk) 2007-03-15
US20140343006A1 (en) 2014-11-20
AU2002329238C1 (en) 2008-08-28
DE122012000038I1 (de) 2012-09-20
FR12C0035I1 (instruction) 2012-06-22
LU92008I2 (fr) 2012-07-24
JP5247661B2 (ja) 2013-07-24
FR22C1036I1 (fr) 2022-09-09
AP1610A (en) 2006-05-08
HRP20040096A2 (en) 2004-06-30
NO20040633L (no) 2004-03-12
HUP0401346A3 (en) 2009-03-02
ES2368996T3 (es) 2011-11-24
LTPA2022515I1 (instruction) 2022-08-25
CY2012012I1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
PL216398B1 (pl) Pochodna pirymidyny i jej zastosowanie oraz kompozycja ją zawierająca i pochodna benzenu
JP5230050B2 (ja) Ｈｉｖ複製阻害剤
ES2371923T3 (es) 5-heterociclil-pirimidinas que inhiben el vih.
PL204427B1 (pl) Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna
EP1797047B1 (en) Hiv inhibiting 5-substituted pyrimidines
HK1145449B (en) Hiv inhibiting pyrimidines derivatives
HK1070066B (en) Hiv inhibiting pyrimidines derivatives

Legal Events

Date Code Title Description
RECP Rectifications of patent specification